申请人:Eli Lilly and Company
公开号:US03956495A1
公开(公告)日:1976-05-11
2,4-diaminoquinazolines are employed as antithrombotic agents and have the following general formula: ##SPC1## Wherein R.sub.1 and R.sub.2 are monovalent groups independently selected from the group consisting of ##EQU1## wherein R.sub.4 and R.sub.5 independently are selected from the group consisting of hydrogen, alkyl, and cycloalkyl, with the proviso that both R.sub.4 and R.sub.5 cannot be cycloalkyl, ##EQU2## wherein R.sub.6, R.sub.7, and R.sub.8 independently are selected from the group consisting of hydrogen and alkyl, and A is a divalent organic group having from two to about six carbon atoms such that the two nitrogen atoms are separated by at least two carbon atoms, and C. heterocyclic-amino, and R.sub.3 is a monovalent group selected from the group consisting of hydrogen, halogen, and alkyl.
2,4-二氨基喹唑啉被用作抗血栓药物,具有以下一般公式:其中R.sub.1和R.sub.2是从以下组成的单价基团中独立选择的:其中R.sub.4和R.sub.5独立地选自氢、烷基和环烷基组成的组,但R.sub.4和R.sub.5不能同时为环烷基;其中R.sub.6、R.sub.7和R.sub.8独立地选自氢和烷基组成的组,A是一个具有两到约六个碳原子的双价有机基团,使得两个氮原子至少被两个碳原子分隔,并且C.杂环氨基,R.sub.3是从氢、卤素和烷基组成的单价基团中选择的。